Trials / Not Yet Recruiting
Not Yet RecruitingNCT07528352
External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
REBEL: A Phase 1b Study on the Safety and Feasibility of External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- University of Utah · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical trial is to assess the safety and tolerability of ration therapy followed by receiving epcoritamab or glofitamab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Epcoritamab | Epcoritamab will be administered per standard of care. |
| DRUG | Glofitamab | Glofitamab will be administered per standard of care. |
| RADIATION | External Beam Radiation Therapy | Participants will receive radiation therapy for 5 fractions completed on sequential days. |
Timeline
- Start date
- 2026-05-01
- Primary completion
- 2030-05-01
- Completion
- 2031-05-01
- First posted
- 2026-04-14
- Last updated
- 2026-04-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07528352. Inclusion in this directory is not an endorsement.